Dear Boris, Here is Our Summary and analysis of the AAVL Phase2a results in wet AMD: Trial Design: Phase Ha, Randomized, Placebo-Controled, N=32, Single Blind (Outcomes Assessor), Primary end point: Safety; Secondary end points: Best-corrected visual acuity (BCVA); Fovea[ thickness; Decrease in rescue inj